UPDATE 1-Ratiopharm gets at least 10 bids -sources

* 10-plus bids include Teva, Sanofi, Permira, KKR, Advent

* Bids mostly in 2 to 2.5 bln euro range

(Adds background on Teva, Actavis, banks advising Ratiopharm)

By Philipp Halstrick and Quentin Webb

FRANKFURT/LONDON, Nov 11 (Reuters) - German generic drugmaker Ratiopharm has attracted at least 10 first-round bids, several people familiar with the procedure told Reuters on Wednesday, indicating a competitive auction was underway.

The strong initial interest comes despite intense price pressure in Germany -- where Ratiopharm makes half its sales -- and includes several bidders from the private equity industry, which struggled to do any deals of size during the depths of the financial crisis.

Bidders from the healthcare industry include Israel's Teva (TEVA.TA), Mylan (MYL.O) of the United States, Sanofi-Aventis (SASY.PA) of France, China's Sinopharm (1099.HK) and Actavis of Iceland, the sources said.

Buyout firms participating in the round of bids, which were non-binding, include TPG [TPG.UL], Advent in collaboration with Goldman Sachs (GS.N), Permira [PERM.UL] and KKR [KKR.UL].

One source said EQT had also filed a bid.